C. Decroisette

2.1k total citations
50 papers, 706 citations indexed

About

C. Decroisette is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, C. Decroisette has authored 50 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 11 papers in Surgery. Recurrent topics in C. Decroisette's work include Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Diagnosis and Treatment (14 papers). C. Decroisette is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Cancer Immunotherapy and Biomarkers (20 papers) and Lung Cancer Diagnosis and Treatment (14 papers). C. Decroisette collaborates with scholars based in France, Réunion and United States. C. Decroisette's co-authors include C. Chouaïd, Clarisse Audigier-Valette, H. Doubre, Florian Guisier, L. Falchero, Charles Ricordel, M. Pérol, P. Fournel, I. Monnet and Olivier Bylicki and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

C. Decroisette

43 papers receiving 696 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Decroisette France	11	524	493	130	112	103	50	706
Bo Jin China	17	703 1.3×	527 1.1×	202 1.6×	147 1.3×	134 1.3×	71	972
Sonia Yip Australia	14	361 0.7×	308 0.6×	84 0.6×	83 0.7×	83 0.8×	75	662
Fernando Rivera Spain	13	372 0.7×	331 0.7×	157 1.2×	58 0.5×	174 1.7×	27	612
E. del Barco Spain	17	260 0.5×	341 0.7×	145 1.1×	118 1.1×	95 0.9×	66	629
Ryo Toyozawa Japan	17	629 1.2×	618 1.3×	182 1.4×	105 0.9×	66 0.6×	89	932
Arunee Dechaphunkul Thailand	13	520 1.0×	468 0.9×	190 1.5×	156 1.4×	152 1.5×	62	855
C. Blajman Argentina	9	425 0.8×	446 0.9×	186 1.4×	94 0.8×	180 1.7×	15	759
Virginia Arrazubi Spain	12	235 0.4×	372 0.8×	136 1.0×	109 1.0×	155 1.5×	48	641
Haruko Daga Japan	16	611 1.2×	594 1.2×	181 1.4×	182 1.6×	58 0.6×	92	911
Shujun Yang China	10	380 0.7×	363 0.7×	96 0.7×	89 0.8×	73 0.7×	29	530

Countries citing papers authored by C. Decroisette

Since Specialization

Citations

This map shows the geographic impact of C. Decroisette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Decroisette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Decroisette more than expected).

Fields of papers citing papers by C. Decroisette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Decroisette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Decroisette. The network helps show where C. Decroisette may publish in the future.

Co-authorship network of co-authors of C. Decroisette

This figure shows the co-authorship network connecting the top 25 collaborators of C. Decroisette. A scholar is included among the top collaborators of C. Decroisette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Decroisette. C. Decroisette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.

Blay, Jean‐Yves, Armelle Dufresne, Virginie Avrillon, et al.. (2025). Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers. ESMO Open. 10(1). 104088–104088.

Godbert, B., Élisa Gobbini, M. Zysman, et al.. (2024). 1317P Real-world immunotherapy (IO) rechallenge outcomes with nivolumab (NIV) in advanced non-small cell lung cancer (aNSCLC) in France: LIST study interim results. Annals of Oncology. 35. S838–S839.

Tomasini, Pascale, Emmanuelle Dantony, Charles Ricordel, et al.. (2024). Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study). Lung Cancer. 193. 107843–107843. 4 indexed citations

Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations

Corre, R., Laurent Greillier, Olivier Bylicki, et al.. (2023). Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08–02 study. Journal of Geriatric Oncology. 15(6). 101506–101506. 2 indexed citations

Molinier, O., I. Monnet, C. Decroisette, et al.. (2022). 509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study. Annals of Oncology. 33. S775–S776. 1 indexed citations

Guisier, Florian, R. Descourt, L. Falchero, et al.. (2022). Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study). Clinical Lung Cancer. 23(8). e545–e549. 6 indexed citations

Auliac, J.B., P. Thomas, Olivier Bylicki, et al.. (2022). 937P Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study. Annals of Oncology. 33. S976–S976.

10.

Mascaux, Céline, M. Zysman, Aurélie Swalduz, et al.. (2022). 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer. Annals of Oncology. 33. S49–S50. 5 indexed citations

11.

Descourt, R., Laurent Greillier, M. Pérol, et al.. (2022). First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunology Immunotherapy. 72(1). 91–99. 18 indexed citations

12.

Girard, Nicolas, Etienne Giroux‐Leprieur, Frédérique Giraud, et al.. (2020). 1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study. Annals of Oncology. 31. S857–S857. 1 indexed citations

13.

Besse, Benjamin, Jessica Menis, Paolo Bironzo, et al.. (2020). LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Annals of Oncology. 31. S1211–S1212. 18 indexed citations

14.

Guisier, Florian, Catherine Dubos‐Arvis, F. Viñas, et al.. (2020). Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology. 15(4). 628–636. 215 indexed citations

15.

Confavreux, Cyrille B., Jean‐Baptiste Pialat, Marie Brevet, et al.. (2018). Bone metastases from lung cancer: A paradigm for multidisciplinary onco-rheumatology management. Joint Bone Spine. 86(2). 185–194. 23 indexed citations

16.

Auliac, J.B., M. Pérol, David Planchard, et al.. (2018). Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer. 127. 96–102. 31 indexed citations

17.

Caer, H. Le, Isabelle Borget, R. Corre, et al.. (2017). Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. Journal of Thoracic Disease. 9(10). 3747–3754. 13 indexed citations

18.

Ferretti, G., J. Cadranel, Clarisse Audigier-Valette, et al.. (2014). Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC. Targeted Oncology. 10(2). 247–253. 37 indexed citations

19.

Vergnenègre, A., C. Decroisette, F. Vincent, et al.. (2006). Analyse économique de l’administration d’une chimiothérapie en hospitalisation à domicile (HAD) comparée à l’hospitalisation de jour dans les cancers bronchopulmonaires non à petites cellules de stade IV. Revue des Maladies Respiratoires. 23(3). 255–263. 8 indexed citations

20.

Decroisette, C., et al.. (2006). Analyse médico-économique des métastases osseuses des cancers broncho-pulmonaires. Revue des Maladies Respiratoires. 23(5). 497–502.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact